Paul Tudor Jones’s Adverum Biotechnologies ADVM Stock Holding History

Paul Tudor Jones’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,213	Closed	-$7K	–	2349
2022 Q4	$7K	Sell	1,213 -5,052	-81%	-$38.3K	﹤0.01%	2282
2022 Q3	$60K	Buy	+6,265	New	+$82.3K	﹤0.01%	2182
2016 Q2	–	Sell	-1,942	Closed	-$100K	–	1592
2016 Q1	$100K	Buy	+1,942	New	+$108K	﹤0.01%	1614
2015 Q4	–	Sell	-1,220	Closed	-$101K	–	1614
2015 Q3	$101K	Sell	1,220 -1,090	-47%	-$139K	﹤0.01%	1426
2015 Q2	$375K	Buy	+2,310	New	+$779K	0.01%	962

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Paul Tudor Jones's ADVM Position: Q1 2023 in Review

Paul Tudor Jones sold out of Adverum Biotechnologies (ADVM) in Q1 2023, closing a stake of 1,213 shares — an estimated $7K sold.

Paul Tudor Jones first reported a position in ADVM in Q2 2015 and held it in 5 quarters. The position peaked at $375K in Q2 2015. 55 funds tracked by Wall St. Rank hold ADVM as of Q1 2023.

Paul Tudor Jones reported no remaining Adverum Biotechnologies position as of Q1 2023 after selling out during the quarter.
Paul Tudor Jones sold 1,213 Adverum Biotechnologies shares in Q1 2023, an estimated $7K.
Paul Tudor Jones first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 5 quarters.
Paul Tudor Jones's Adverum Biotechnologies position peaked at $375K in Q2 2015.
55 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2023.

Based on Tudor Investment Corp's 13F filing for Q1 2023, filed 15 May 2023.